Aquaculture Vaccines Market: Size, Dynamics, Regional Share, Trends, Competitor Analysis (2016-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Global Aquaculture Vaccines Market: By Vaccine Type (Inactivated Vaccine, Attenuated Live Vaccine, DNA Vaccine, and Others), By Application (Bacterial Infection, Viral Infections, Combined Bacterial and Viral Infections, and Others), By Route of Administration (Immersion Vaccines, Injection Vaccines, and Oral Vaccines), By Species (Salmon, Seabass and Seabream, Tilapia, Trout, Turbot, and Carp), and Geography (North America, Latin America, Europe, Asia Pacific and Middle East and Africa)

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

The global aquaculture vaccines market is estimated to be valued USD 371.8 million in 2021 and poised to grow at a significant CAGR of 9.6% during forecast period 2022-2028. Due to surge in the of prevalence of bacterial and viral infections among aquaculture species, increase in aquaculture production around the globe, and rise in adoption of vaccines by aquaculture farmers. Development and launch of innovative vaccines to treat various infectious diseases in aquaculture species boosting the revenue growth of the market. For instance, In March 2018, Hipra launched Icthiovac VR/PD injectable vaccine for seabass against Vibriosis and Pasteurellosis in Greece. Apart from the aforementioned dynamics, Raise in funding for the research and development of innovative aquaculture vaccines boost the market over forecast years. For instance, In March 2015, The Scottish Aquaculture Innovation Center (SAIC) has announced it is issuing grants worth almost GBP 950,000 to two major salmon farming research projects proposed by leading farmed salmon companies on sea lice and salmon vaccinations. This report studies give market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, this report includes aquaculture production and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the fish vaccines market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global vaccines market report include suppliers, manufacturers, marketers, policy makers, and aquaculture service providers engaged in global aquaculture vaccines products usage and advocacy.

Key Development:

For instance, in April 2021, CIBA launched Nodavac-R, an injectable recombinant viral nervous necrosis (VNN) vaccine that can effectively prevent VNN caused by RGNNV in fingerlings and prevent vertical transmission in brooders. All fish species, including milkfish, grey mullet, and mangrove red snapper susceptible to VNN, can use the Nodavac-R. CIBA is also developing an oral vaccine that can administer through feed and immersion.

In November 2019, MSD Animal Health launched the AQUAVAC® Strep Sa-Si injectable and dip immersion vaccine against Streptococcis in tilapia fish in Latin America.

Aquaculture Vaccines Market

MARKET SUMMARY
-
9.6% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 9.6%
  • Largest Market– Europe
  • Fastest Growing Market– Latin America

Aquaculture Vaccines Market

  • The report gives historical, current, and future market sizes (US$ Mn) on the basis of vaccine type, application, route of administration, species, and region.
  • The global aquaculture market this report gives comprehensive outlook on aqua vaccines across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
Market Key Players
  • Pharmaq AS (Zoetis, LLC) (Norway)
  • Merck Animal Health (Merck & Co., Inc.) (USA)
  • KoVax Ltd. (Part of Phibro Animal Health) (Israel)
  • Hipra (Spain)
  • Tecnovax SA (Argentina)
Drivers And Restraints

Aquaculture Vaccines Market

Increase in the fish mortality due to certain disease outbreaks driving the growth of aquaculture vaccines market. For instance, in October 2017, approximately 125,000 salmon have died due to a disease outbreak at two fish farms on the Isle of Lewis due to bacterium Pasturella Skyensis infection. In addition, surge in population demand for the healthy fish products, demand for animal protein, government support for the aquaculture immunization programs, rise in adoption of aquaculture vaccines in the developed and developing nations are boost the aquaculture vaccines market over the forecast years. Moreover, increase in the international trading of aquaculture species immense boost the global aquaculture vaccines over the forecast period.


Europe got significant share

Aquaculture Vaccines Market

Europe accounted for larger revenue share through 2015-2019 and the same trend is projected to follow over 2020-2026 owing to increase in the adoption of aquaculture vaccines in Norway, Russia, U.K, Greece, and other European countries coupled with increase in the aquaculture farming in the region are boosting the market growth. Latin America market projected to exhibit significant growth owing launch of newer products into the Chile, Mexico, Brazil, and other Latin America countries is expected to enhance the market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

What we have covered in our Aquaculture Vaccines Report

  • Why there is a shift towards consumption of fish?
  • Species Production by Country and Region
  • Benefits of Immersion, Injection and Oral Vaccines
  • Fast Growing Countries in Aquaculture Production
  • Why aquaculture vaccines are less preferred in the Asia Pacific Region?
  • Research and Development Activities of Various Aquaculture Vaccine Companies and their Product Pipeline?
  • Why Zoetis and Phibro Acquired Fish Vaccine Manufacturers?
  • Why Canada is dominating the North America Aquaculture Vaccines Market?
  • Commercially Available Aquaculture Vaccines in the Market ?
Segmentation

Aquaculture Vaccines Market


Location

GEOGRAPHY

Frequently Asked Questions

The global aquaculture vaccine market is valued at USD 450 Million in 2021 and is projected to reach 700 Million by 2028.

The CAGR of the aquaculture vaccines market is 7.6% over the forecast period (2022 – 2028)

Inactivated vaccine type dominates the aquaculture vaccine product segment.

Norway is the big market in the aquaculture vaccines market

Zoetis (Pharmaq), MSD Animal Health, Elanco, and Virbac are the key market players in the aquaculture vaccines market.


Report

Company Profile

  • Pharmaq AS (Zoetis, LLC) (Norway)
  • Merck Animal Health (Merck & Co., Inc.) (USA)
  • KoVax Ltd. (Part of Phibro Animal Health) (Israel)
  • Hipra (Spain)
  • Tecnovax SA (Argentina)
  • Veterquimica S.A. (Chile)
  • Nisseiken Co. Ltd. (Japan)
  • Virbac S.A. (France)
  • Elanco (USA)
  • Kyoritsuseiyaku Corporation (Japan)

Description

The global aquaculture vaccines market is estimated to be valued USD 371.8 million in 2021 and poised to grow at a significant CAGR of 9.6% during forecast period 2022-2028. Due to surge in the of prevalence of bacterial and viral infections among aquaculture species, increase in aquaculture production around the globe, and rise in adoption of vaccines by aquaculture farmers. Development and launch of innovative vaccines to treat various infectious diseases in aquaculture species boosting the revenue growth of the market. For instance, In March 2018, Hipra launched Icthiovac VR/PD injectable vaccine for seabass against Vibriosis and Pasteurellosis in Greece. Apart from the aforementioned dynamics, Raise in funding for the research and development of innovative aquaculture vaccines boost the market over forecast years. For instance, In March 2015, The Scottish Aquaculture Innovation Center (SAIC) has announced it is issuing grants worth almost GBP 950,000 to two major salmon farming research projects proposed by leading farmed salmon companies on sea lice and salmon vaccinations. This report studies give market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, this report includes aquaculture production and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the fish vaccines market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global vaccines market report include suppliers, manufacturers, marketers, policy makers, and aquaculture service providers engaged in global aquaculture vaccines products usage and advocacy.

Key Development:

For instance, in April 2021, CIBA launched Nodavac-R, an injectable recombinant viral nervous necrosis (VNN) vaccine that can effectively prevent VNN caused by RGNNV in fingerlings and prevent vertical transmission in brooders. All fish species, including milkfish, grey mullet, and mangrove red snapper susceptible to VNN, can use the Nodavac-R. CIBA is also developing an oral vaccine that can administer through feed and immersion.

In November 2019, MSD Animal Health launched the AQUAVAC® Strep Sa-Si injectable and dip immersion vaccine against Streptococcis in tilapia fish in Latin America.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX